# Samuel Levy

> Samuel Levy is a private equity investor at Lauxera Capital Partners backing Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Lauxera Capital Partners](https://shizune.co/investors/profile/lauxera-capital-partners)
- Location: Paris, France
- Total investments: 5
- Last investment: Feb 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/samuel-levy-543b001/

Samuel Levy is a private equity investor at Lauxera Capital Partners in Paris focused on Health Care and Medical Device. Samuel Levy is the Founding Partner at Lauxera Capital. He attended the Yale University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 80% |
| Medical Device | 4 | 80% |
| Apps | 1 | 20% |
| Fitness | 1 | 20% |
| Medical | 1 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 2 | 40% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 1 | 20% |
| Germany | 1 | 20% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OrganOx | OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M | Venture - Series Unknown | Feb 24, 2025 |  |
| Acandis | Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52.1M | Private Equity | Jan 22, 2025 |  |
| Acandis | Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52M |  | Jan 22, 2025 |  |
| Natural Cycles | Natural Cycles offers a contraceptive app, spearheading digital contraception, a new category in female reproductive health.Users measure their basal body temperature in the morning and the app computes the temperature (and other relevant data like levels of luteinizing hormone) through an algorithm to calculate whether they are fertile or not.Natural Cycles’ subscription product relies on an algorithmic method to predict which days women are fertile during their monthly cycle — with an in-app color-coded calendar informing users if they could have unprotected sex on a given day or not.Women using the app are required to measure and input their body temperature daily using a basal thermometer. Natural Cycles relies on this and other individual data inputs to algorithmically calculate the probability of the user being fertile on each day in her cycle. | $55M | Series C | May 29, 2024 |  |
| Veranex | Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtechinnovations. |  | Private Equity | May 19, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [Accelmed](https://shizune.co/investors/profile/accelmed) — VC Fund, 1 deal together
- [Bonnier Capital](https://shizune.co/investors/profile/bonnier-ventures) — VC Fund, 1 deal together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 1 deal together
- [EQT Ventures](https://shizune.co/investors/profile/eqtventures) — VC Fund, 1 deal together
- [Headline](https://shizune.co/investors/profile/headlinevc) — VC Fund, 1 deal together
- [Heartcore Capital](https://shizune.co/investors/profile/heartcore-capital) — VC Fund, 1 deal together

## About Lauxera Capital Partners

VC Fund · Paris, France

Lauxera Capital Partners is an independent, international, healthcare-focused asset management company. Our growth equity investments focus primarily on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies. Led by entrepreneurial company builders and seasoned healthcare investors with experienceacross international markets, we empower European healthtech entrepreneurs to deliver the growth promised by their innovations.Lauxera was created in 2020 and has offices in Paris and San Francisco.

3 contacts available at Lauxera Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alex Slack | Co-Founder | https://shizune.co/investors/profile/alex-slack |
| Samuel Levy | Founding Partner | https://shizune.co/investors/profile/dr-samuel-levy |
| Victor Decrion | Managing Partner | https://shizune.co/investors/profile/victor-decrion-1ffa |

## Similar investors

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

## FAQ

### What does Samuel Levy invest in?

Samuel Levy invests primarily in Health Care, Medical Device and Apps startups, most often at Private Equity and Series C stage. Most of the 5 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Samuel Levy last invest?

The most recent investment recorded for Samuel Levy closed in Feb 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co